Effectiveness and safety of azvudine in the treatment of COVID-19 patients: a retrospective cohort study using propensity score matching [PDF]
Frontiers in Cellular and Infection MicrobiologyBackgroundClinical trials have demonstrated the efficacy of azvudine in alleviating clinical symptoms among patients with coronavirus disease 2019 (COVID-19).
Jing Zhang +5 more
doaj +4 more sources
Adherence and recommended optimal treatment to Azvudine application for the treatment of outpatient COVID-19 patients: A real-world retrospective study [PDF]
HeliyonBackground: Azvudine was approved for the treatment of coronavirus disease 2019 (COVID-19) in China and has been widely used since the outbreak in December 2022. However, real-world research on the adherence of Azvudine is lacking.
Zhuoling An, Yushu Wang
exaly +4 more sources
Azvudine for the Treatment of COVID‐19 in Pre‐Existing Cardiovascular Diseases: A Single‐Center, Real‐World Experience [PDF]
Advanced ScienceCOVID‐19 can lead to adverse outcomes in patients with pre‐existing diseases. Azvudine has been approved for treating COVID‐19 in China, but the real‐world data is limited. It is aimed to investigate the efficacy of Azvudine in patients with COVID‐19 and
Hong-Da Zhang
exaly +3 more sources
Real-world efficacy and safety of azvudine in hospitalized older patients with COVID-19 during the omicron wave in China: A retrospective cohort study [PDF]
Acta Pharmaceutica Sinica BDebates persist regarding the efficacy and safety of azvudine, particularly its real-world outcomes. This study involved patients aged ≥60 years who were admitted to 25 hospitals in mainland China with confirmed SARS-CoV-2 infection between December 1 ...
Yubing Zhu, Xingang Li, Deshi Dong
exaly +4 more sources
Efficacy and safety evaluation of Azvudine in the prospective treatment of COVID-19 based on four phase III clinical trials [PDF]
Frontiers in Pharmacology, 2023 Azvudine (FNC) is a synthetic nucleoside analog used to treat adult patients living with human immunodeficiency virus-1 (HIV-1) infection with high viral load.
Ke-Wei Zhu
doaj +3 more sources
A retrospective cohort study of the efficacy and safety of oral azvudine versus nirmatrelvir/ritonavir in elderly hospitalized COVID-19 patients aged over 60 years [PDF]
Acta Pharmaceutica Sinica BAzvudine and nirmatrelvir/ritonavir (Paxlovid) are recommended for COVID-19 treatment in China, but their safety and efficacy in the elderly population are not fully known.
Zhigang Ren
exaly +4 more sources
Comparative analysis of the safety and effectiveness of Nirmatrelvir-Ritonavir and Azvudine in older patients with COVID-19: a retrospective study from a tertiary hospital in China [PDF]
Frontiers in PharmacologyIntroduction: Numerous studies have explored the treatment outcomes of Nirmatrelvir-Ritonavir and Azvudine in older patients with COVID-19. However, direct comparisons between these two drugs are still relatively limited.
Nan Shang
exaly +4 more sources
Azvudine reduces the in-hospital mortality of COVID-19 patients: A retrospective cohort study
Acta Pharmaceutica Sinica B, 2023 In our retrospective cohort study, we aim to explore whether Azvudine modifies the risk of death in COVID-19 patients. It was conducted on the medical records of patients, consecutively admitted for COVID-19 pneumonia to two hospitals in Chongqing, China.
Kaican Zong +5 more
exaly +3 more sources
Heliyon, 2023 Background: Although vaccinations and antiviral drugs are widely used in the clinical treatment worldwide, there is little investigation on the clinical outcomes and effectiveness of oral Azvudine tablets (FNC) treatment in COVID-19 hospitalized patients.
Yanli Zhao, Gan Gao, Wenhui Li
exaly +3 more sources
Elevated INR in a COVID-19 patient after concomitant administration of azvudine and anticoagulants
Frontiers in Pharmacology, 2023 Background: Azvudine (FNC) is a promising treatment candidate for managing coronavirus disease 2019 (COVID-19). However, drug interactions with azvudine have been poorly studied, especially with no reported cases of azvudine with anticoagulants such as ...
Xi Zhang +8 more
exaly +3 more sources